Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Just a few more quick points on our financials, if you look at our cash flow statement you’ll see we’re reporting an operating cash burn of $15.1 million and also our P&L statement shows $14.8 million in R&D expense. So, if you put these two numbers together, this statement show that the cash burn is due to the R&D costs, not really a surprise there.
These R&D costs are however starting to really pay off for us.
$15 million in milestones timed and frontloaded as they are, provides us with much needed funding for the continued and expedited development of additional Abuse-Deterrent opioid products
.
My advice :
BUY ELTP!
GREEN CLOSE would be nice
I see 0.0020 on a chart, for today
I see 0.0018 on 1 day chart..
"Market cap is only $133,751. Seriously undervalued."
Exactly
BETS
.
SeanieMac International, Ltd. Seeking to reduce Authorized shares from 2,000,000,000 to 850,000,000
.
http://ih.advfn.com/p.php?pid=nmona&article=65588561
BETS
.
SeanieMac International, Ltd. Seeking to reduce Authorized shares from 2,000,000,000 to 850,000,000
.
http://ih.advfn.com/p.php?pid=nmona&article=65588561
ELTP News !
http://money.cnn.com/news/newsfeeds/articles/globenewswire/10115711.htm
Elite is creating both a diverse range of opioid abuse-deterrent products using their proprietary technology and building a foundation of attractive niche generic drugs."
.
Elite Pharmaceuticals Awarded Second Canadian Patent for Abuse Deterrent Drug Formulation
Read more: http://www.nasdaq.com/press-release/elite-pharmaceuticals-awarded-second-canadian-patent-for-abuse-deterrent-drug-formulation-20141216-00424#ixzz3M4dDyLIu
$ELTP
$ELTP -ELTP revenue growing Q over Q
-ELTP Initiate Pivotal Bioequivalence Study for ELI-201
-ELTP recieve 5mil from Novel stake
-ELTP Begin Human Abuse Liability Studies for ELI-200
-ELTP Initiates Pivotal Bioequivalence Study for Third Opioid Abuse Deterrent Product
-ELTP Granted New Patent for Abuse Deterrent Technology
-ELTP Secures Funding Commitment of Up to $40 Million From Lincoln Park Capital Fund, LLC
-ELTP Expands Abuse Deterrent Technology Patent Portfolio Internationally
-ELTPReports Successful Pivotal Bioequivalence Study for Abuse Deterrent Product ELI-200
-ELTP Reports positive Results of Pilot Bioequivalence Study for ELI-201
-ELTP Initiates Pivotal Bioequivalence Study for Second Opioid Abuse Deterrent Product
$ELTP
-ELTP revenue growing Q over Q
-ELTP Initiate Pivotal Bioequivalence Study for ELI-201
-ELTP recieve 5mil from Novel stake
-ELTP Begin Human Abuse Liability Studies for ELI-200
-ELTP Initiates Pivotal Bioequivalence Study for Third Opioid Abuse Deterrent Product
-ELTP Granted New Patent for Abuse Deterrent Technology
-ELTP Secures Funding Commitment of Up to $40 Million From Lincoln Park Capital Fund, LLC
-ELTP Expands Abuse Deterrent Technology Patent Portfolio Internationally
-ELTPReports Successful Pivotal Bioequivalence Study for Abuse Deterrent Product ELI-200
-ELTP Reports positive Results of Pilot Bioequivalence Study for ELI-201
-ELTP Initiates Pivotal Bioequivalence Study for Second Opioid Abuse Deterrent Product
$ELTP is gonna be a winner folks !!!
$ELTP gonna be a winner folks !!!
RSI 26.5
Earnings Call Transcript :
"If you look at the balance sheet $7.6 million in cash, $4.1 million in working capital and $2.5 million in inventory.
These are the resources and a critical mass to support the financial requirements of commercializing ELI-200 as our first abuse resistant opioid. The resources are in place and they are available and that’s a big deal as in the past finance was always an impediment to R&D. That’s no longer the case and our financials, both the P&L and the balance sheet clearly demonstrate this. So we’re well set to continue with our activities as planned.“
Our R&D activities and pipeline are very rich. We have several active R&D projects. With a small company like ours you need to prioritize and not take on too much but we have more than half a dozen that are active. Our focus remains on ELI-200. The ELI-200 had undergone vigorous testing and clinical trials and lab trials this year. We definitely have a successful formulation and technology."...
http://seekingalpha.com/article/2696615-elite-pharmaceuticals-eltp-ceo-nasrat-hakim-on-q2-2015-results-earnings-call-transcript?page=2
Ok, thanks.
So we should see a PR on results soon and later on ELI-201 BE study results ?
We have several other products in development that we’ve updated to you on. We’ll start with the clinical trials for ELI-201, same thing with ELI-202. Again, the results and data will be available in October probably...
Does this mean results of a pivotal bioequivalence study ELI-202 from May 19, 2014 ?
http://globenewswire.com/news-release/2014/05/19/637479/10082202/en/Elite-Pharmaceuticals-Initiates-Pivotal-Bioequivalence-Study-for-Third-Opioid-Abuse-Deterrent-Product.html
PVCT back to 1 and above!
http://investorshub.advfn.com/Provectus-Biopharmaceuticals-Inc-PVCT-1285/
Provectus Biopharmaceuticals Inc. (PVCT)!!!
ELTP
ELTP_Elite Pharmaceuticals
...
.
3/27/2014 Elite Pharmaceuticals Appoints Barbara Ellison as Vice President of Quality Operations and Regulatory Affairs
- New Hire Brings Track Record of Success
.
3/24/2014 Elite Pharmaceuticals Announces Supplemental Application for Site Transfer of Isradipine
.
3/10/2014 Elite Pharmaceuticals Expands Abuse Deterrent Technology Patent Portfolio Internationally
.
3/5/2014 Elite Pharmaceuticals Reports Successful Pivotal Bioequivalence Study for Abuse Deterrent Product ELI-200
.
2/18/2014 Elite Pharmaceuticals Reports Results of Pilot Bioequivalence Study for ELI-201.
...We are delighted with the results from our clinical studies and pleased to have confirmation of the formulation for our extended release product.
.
1/14/2014 Elite Pharmaceuticals Initiates Pivotal Bioequivalence Study for Second Opioid Abuse Deterrent Product
.
12/5/2013 Elite Pharmaceuticals Initiates Pilot Bioequivalence Study for ELI-201
.
11/14/2013 Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2014
...Revenues Increase by 83%, Product Development Accelerating
ELTP_Elite Pharmaceuticals !
3/27/2014 Elite Pharmaceuticals Appoints Barbara Ellison as Vice President of Quality Operations and Regulatory Affairs
- New Hire Brings Track Record of Success
.
3/24/2014 Elite Pharmaceuticals Announces Supplemental Application for Site Transfer of Isradipine
.
3/10/2014 Elite Pharmaceuticals Expands Abuse Deterrent Technology Patent Portfolio Internationally
.
3/5/2014 Elite Pharmaceuticals Reports Successful Pivotal Bioequivalence Study for Abuse Deterrent Product ELI-200
.
2/18/2014 Elite Pharmaceuticals Reports Results of Pilot Bioequivalence Study for ELI-201.
...We are delighted with the results from our clinical studies and pleased to have confirmation of the formulation for our extended release product.
.
1/14/2014 Elite Pharmaceuticals Initiates Pivotal Bioequivalence Study for Second Opioid Abuse Deterrent Product
.
12/5/2013 Elite Pharmaceuticals Initiates Pilot Bioequivalence Study for ELI-201
.
11/14/2013 Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2014
...Revenues Increase by 83%, Product Development Accelerating
As of the Record Date, the total shares of Common Stock issued and outstanding and reserved for issuance upon the exercise of outstanding warrants, options, and the conversion of outstanding shares of preferred stock totaled ~ shares, including:
556,063,019 shares of Common Stock;
101,143,933 shares reserved for issuance pursuant to warrants to purchase Common Stock
2,075,666 shares reserved for issuance pursuant to options to purchase Common Stock;
148,917,143 shares reserved for issuance upon the conversion of shares of our outstanding series of preferred stock;
Total : 808,199,761 shares
ELTP
.
"Elite is now in the best financial, operational, and product development position in its history"
http://ih.advfn.com/p.php?pid=nmona&article=60166774
ELTP Conference Call Today--3 PM
The Company will host a conference call to discuss the results of operations and provide an update on recent business developments on Monday, November 18, 2013 at 3:00 PM ET.
Company executives will also conduct a question and answer session following their remarks.
To access the conference call:
Domestic callers: (800) 346-7359
International callers: (973) 528-0008
Conference Entry Code: 98840
AQUM News !
Buy low !
Urban Ag Corp (OTC:AQUM) (the "Company"), announced today that B&R Telephone ("B&R"), an operating unit of its wholly-owned subsidiary Green Wire Enterprises, Inc., has been awarded a service agreement to provide voice and data services
http://ih.advfn.com/p.php?pid=nmona&article=59983759
AQUM News !
Buy low
Urban Ag Corp (OTC:AQUM) (the "Company"), announced today that B&R Telephone ("B&R"), an operating unit of its wholly-owned subsidiary Green Wire Enterprises, Inc., has been awarded a service agreement to provide voice and data services
http://ih.advfn.com/p.php?pid=nmona&article=59983759
AQUM This brand new subbie could be the talk of the town tomorrow!
Read more at http://www2.thestockmarketwatch.com/newsletters/2013/10/31/this-brand-new-subbie-could-be-the-talk-of-the-town-tomorrow/#oDesCgKoehR6jiZ8.99
Urban Ag Corp (AQUM)
AQUM just starting ! :)
.
http://www2.thestockmarketwatch.com/newsletters/2013/10/31/this-brand-new-subbie-could-be-the-talk-of-the-town-tomorrow/#muQ2PM1y7i8cIgX7.99
.
Urban Ag Corp (AQUM)
This will go up !
Fuse Science, Inc. (DROP)
http://investorshub.advfn.com/Fuse-Science-Inc-DROP-8874/
Fuse Science, Inc. (DROP)
Next week !!! :)
!!! E L T P !!!
Revenues for the quarter ended March 31, 2013, were exceptionally strong, totaling $1.5 million, the highest quarterly revenue level in corporate history, 131% above quarterly revenues for the comparable period of the prior year. The large increases in revenues are the result of the successful launch and strong growth in new product revenues which have mostly been created during the past 18 months.
.
http://investorshub.advfn.com/boards/board.aspx?board_id=15170
E L T P ! ! !
Elite Pharmaceuticals (ELTP)
,
We are anticipating that, with the growth of the generic phentermine product, the contract manufacturing of methadone, Lodrane D® immediate release, Hydromorphone, Phendimetrazine and, the eventual launch of the generic naltrexone, generic phentermine capsule products and other opportunities in our pipeline, Elite eventually could be profitable.
.
All these products were launched in 24 months
From 0 to 7...
.
http://ih.advfn.com/p.php?pid=webchart&btn=s_ok&ctl00%24sb3%24tbq1=Get+Quote&as_values_IH=&ctl00%24sb3%24stb1=Search+iHub&symbol=OTCBB%3AELTP&s_ok=Get+Chart&period=8&drawmode=0&size=19&volume=1
Buying opp on ELTP right now !
.
With CFP which means "A PROFITABLE COMPANY WITH GROWTH", 8 products on line (soon with Naltrexone), doubled facilities with packaging line...